Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Corline Biomedical AB (publ) in connection with a directed share issue
Mandate

Vinge has advised Corline Biomedical AB (publ) in connection with a directed share issue

March 30, 2021 Capital Markets and Public M&A

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process.

Corline intends to use the issue proceeds to continue the development of Renaparin® in phase 2 clinical development to interim data, build the organisation to increase proceeds to the medical technology branch, improve the financial flexibility and strengthen the working capital.

Vinge’s team has consisted of Dain Hård Nevonen, Amanda Knutsson and Clara Sohlberg.

Related

Vinge advises in connection with data center provider EcoDataCenter’s issue of SEK 500 million senior unsecured bonds

Vinge has advised ABG Sundal Collier in connection with EcoDC Holding AB (publ)'s issue of SEK 500 million senior unsecured bonds, within a framework of up to SEK 2 billion.
November 28, 2025

Vinge has advised Northmill Group AB in connection with the issuance of tier 2 capital bonds (T2)

 Vinge has advised Northmill Group AB in connection with its successful issuance of SEK 100 million tier 2 capital bonds (T2) with a floating rate interest of 3-month STIBOR + 650 basis points.
November 26, 2025

Vinge has advised Fortinova Fastigheter in connection with its uplisting to Nasdaq Stockholm

 Vinge has advised Fortinova Fastigheter AB (publ) in connection with its list change from Nasdaq First North Premier Growth Market to Nasdaq Stockholm. The prospectus was published on 12 November 2025 and the trading on Nasdaq Stockholm commenced on 19 November 2025, five years to the day since the first listing.
November 19, 2025